Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-25-100450
Filing Date
2025-07-31
Accepted
2025-07-30 18:07:26
Documents
7
Period of Report
2025-07-30

Document Format Files

Seq Description Document Type Size
1 6-K sndl-6-k-2025_q2.htm 6-K 23372
2 EX-99.1 sndl-ex99_1.htm EX-99.1 2542745
3 EX-99.2 sndl-ex99_2.htm EX-99.2 1406937
4 EX-99.3 sndl-ex99_3.htm EX-99.3 24392
5 EX-99.4 sndl-ex99_4.htm EX-99.4 24605
6 GRAPHIC img260723042_0.jpg GRAPHIC 15922
7 GRAPHIC img261646563_0.jpg GRAPHIC 15922
  Complete submission text file 0000950170-25-100450.txt   4067427
Mailing Address 919 11 AVENUE SW SUITE 300 CALGARY Canada (Federal Level)
Business Address 919 11 AVENUE SW SUITE 300 CALGARY Canada (Federal Level) 14039485227
SNDL Inc. (Filer) CIK: 0001766600 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39005 | Film No.: 251168464
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)